| Old Articles: <Older 3281-3290 Newer> |
|---|
 |
Bio-IT World
November 2006
Alan S. Louie |
Signs of Life in Life Sciences IT Spending Pharmaceutical and other life science companies are confronting explosive growth in the volume of data being generated from R&D programs including high-throughput discovery instrumentation, molecular imaging (pre-clinical and clinical), and access to external data sources.   |
Bio-IT World
November 2006
Kevin Davies |
The Quest to Make Sequence Sense With the human genome sequenced several years ago, the challenge for biopharma organizations mining this invaluable trove of data is evolving. |
Bio-IT World
November 2006
Kevin Davies |
Jubilant Curries Favor with BioPharma The explosion of drug discovery and development operations in India is epitomized by the success of several companies. Quietly building on a decade of experience in computational and bio-IT fields, JBL is rapidly pushing into a suite of drug discovery and development activities. |
Bio-IT World
November 2006
Kevin Davies |
Building a Bridge Over Pharma with IT More than 100 enthusiastic delegates bridging the full breadth of the drug development pipeline gathered recently for the second annual Bridging Pharma and IT conference. Here are some highlights. |
Bio-IT World
November 2006
Mark D. Uehling |
Putting EDC on the Fast Track There's no escaping the imposing numbers of choices in launching a clinical trial using electronic data capture. Is there a better way? Clinical trial consultant Fast Track Systems says it has one. |
Bio-IT World
November 2006
Kevin Davies |
Compute for the Cure Computational comparison offers a seductive new approach to identify new drugs for disease, as well as re-purposing existing drugs. |
BusinessWeek
November 20, 2006
Arlene Weintraub |
Is Cell Therapeutics In Remission? Battered biotech Cell Therapeutics' controversial CEO has won over Novartis, but investors are wary. |
HBS Working Knowledge
November 13, 2006
Sean Silverthorne |
Science Business: What Happened to Biotech? The biotech industry has underperformed expectations, caught in the conflicting objectives and requirements between science and business. |
The Motley Fool
November 13, 2006
Brian Lawler |
King Not Loving Its Shareholders King Pharmaceuticals appears to be a company with stagnating operations, trying to grow sales via licensing or acquiring new drugs, with (at best) a shaky handling of its accounting practices. Investors, take note. |
The Motley Fool
November 13, 2006
Brian Lawler |
Kos' Swan Song The drug company releases what will probably be its last earnings announcement before a buyout by Abbot Labs. Investors, take note. |
| <Older 3281-3290 Newer> Return to current articles. |
